| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 25 | 2022 | 1145 | 5.070 |
Why?
|
| Lung Neoplasms | 33 | 2022 | 2386 | 4.630 |
Why?
|
| Chemoradiotherapy | 19 | 2022 | 327 | 3.600 |
Why?
|
| Radiosurgery | 15 | 2025 | 316 | 3.500 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2021 | 1087 | 2.890 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 148 | 2.060 |
Why?
|
| Neoplasm Staging | 36 | 2022 | 2042 | 2.030 |
Why?
|
| Oropharyngeal Neoplasms | 7 | 2022 | 149 | 2.010 |
Why?
|
| Neoadjuvant Therapy | 12 | 2017 | 449 | 1.970 |
Why?
|
| Adenocarcinoma | 9 | 2020 | 1192 | 1.890 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2019 | 188 | 1.600 |
Why?
|
| Databases, Factual | 15 | 2022 | 1010 | 1.550 |
Why?
|
| Brain Neoplasms | 10 | 2025 | 848 | 1.390 |
Why?
|
| Carcinoma, Large Cell | 4 | 2021 | 39 | 1.250 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2020 | 39 | 1.230 |
Why?
|
| Middle Aged | 65 | 2025 | 28208 | 1.220 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2019 | 204 | 1.180 |
Why?
|
| Aged | 55 | 2025 | 20848 | 1.160 |
Why?
|
| Glioblastoma | 5 | 2025 | 285 | 1.140 |
Why?
|
| Male | 75 | 2025 | 45686 | 1.130 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 301 | 1.090 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 517 | 1.070 |
Why?
|
| Female | 74 | 2025 | 49872 | 1.050 |
Why?
|
| Aged, 80 and over | 29 | 2025 | 7215 | 0.990 |
Why?
|
| Radiotherapy Dosage | 13 | 2019 | 476 | 0.980 |
Why?
|
| SEER Program | 17 | 2025 | 235 | 0.960 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2022 | 129 | 0.940 |
Why?
|
| United States | 32 | 2025 | 7764 | 0.920 |
Why?
|
| Survival Rate | 17 | 2025 | 1971 | 0.900 |
Why?
|
| Survival Analysis | 14 | 2019 | 1540 | 0.890 |
Why?
|
| Humans | 97 | 2025 | 95802 | 0.890 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 883 | 0.860 |
Why?
|
| Registries | 6 | 2025 | 985 | 0.860 |
Why?
|
| Adult | 49 | 2025 | 28578 | 0.860 |
Why?
|
| Early Detection of Cancer | 4 | 2021 | 484 | 0.860 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 196 | 0.850 |
Why?
|
| Combined Modality Therapy | 14 | 2019 | 1739 | 0.850 |
Why?
|
| Young Adult | 28 | 2025 | 7026 | 0.850 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 900 | 0.840 |
Why?
|
| Palliative Care | 3 | 2018 | 271 | 0.830 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 3904 | 0.780 |
Why?
|
| Transplantation Conditioning | 7 | 2025 | 383 | 0.750 |
Why?
|
| Esophageal Neoplasms | 3 | 2016 | 345 | 0.740 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1463 | 0.730 |
Why?
|
| Neoplasms, Second Primary | 2 | 2015 | 245 | 0.660 |
Why?
|
| Healthcare Disparities | 5 | 2021 | 491 | 0.660 |
Why?
|
| Extremities | 2 | 2013 | 179 | 0.630 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2017 | 47 | 0.630 |
Why?
|
| Lymph Nodes | 4 | 2020 | 554 | 0.620 |
Why?
|
| Adolescent | 20 | 2025 | 9873 | 0.620 |
Why?
|
| Radiotherapy, Conformal | 3 | 2017 | 89 | 0.620 |
Why?
|
| Sarcoma | 2 | 2013 | 224 | 0.610 |
Why?
|
| Retrospective Studies | 26 | 2024 | 10273 | 0.590 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 1008 | 0.590 |
Why?
|
| Prognosis | 14 | 2022 | 3990 | 0.580 |
Why?
|
| Cohort Studies | 13 | 2020 | 3106 | 0.560 |
Why?
|
| Treatment Outcome | 19 | 2022 | 9167 | 0.550 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2020 | 315 | 0.550 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 491 | 0.550 |
Why?
|
| Stomach Neoplasms | 3 | 2017 | 310 | 0.540 |
Why?
|
| Carcinoma | 5 | 2022 | 444 | 0.540 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 51 | 0.530 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 22 | 0.530 |
Why?
|
| Mass Screening | 2 | 2021 | 710 | 0.530 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2025 | 92 | 0.520 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 42 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 942 | 0.490 |
Why?
|
| Mouth Neoplasms | 2 | 2020 | 202 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 2773 | 0.480 |
Why?
|
| Esophagectomy | 3 | 2016 | 92 | 0.460 |
Why?
|
| Whole-Body Irradiation | 5 | 2025 | 70 | 0.450 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 66 | 0.450 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 151 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 647 | 0.440 |
Why?
|
| Mortality | 2 | 2016 | 154 | 0.440 |
Why?
|
| Insurance, Health | 5 | 2016 | 182 | 0.440 |
Why?
|
| Propensity Score | 8 | 2020 | 180 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 2605 | 0.430 |
Why?
|
| Insurance Coverage | 4 | 2017 | 144 | 0.420 |
Why?
|
| Tumor Burden | 6 | 2020 | 322 | 0.410 |
Why?
|
| Preoperative Care | 2 | 2017 | 417 | 0.400 |
Why?
|
| Central Nervous System | 1 | 2014 | 153 | 0.390 |
Why?
|
| Immunotherapy | 1 | 2019 | 766 | 0.390 |
Why?
|
| Radiation Injuries | 1 | 2014 | 159 | 0.380 |
Why?
|
| Pneumonectomy | 1 | 2015 | 217 | 0.380 |
Why?
|
| Organs at Risk | 5 | 2019 | 48 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 299 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 1021 | 0.350 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 1194 | 0.340 |
Why?
|
| Ependymoma | 1 | 2011 | 29 | 0.340 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 3155 | 0.320 |
Why?
|
| Logistic Models | 4 | 2020 | 1267 | 0.310 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 640 | 0.310 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 506 | 0.310 |
Why?
|
| Brachytherapy | 3 | 2015 | 127 | 0.310 |
Why?
|
| Papillomaviridae | 4 | 2022 | 180 | 0.300 |
Why?
|
| Myeloablative Agonists | 3 | 2025 | 38 | 0.290 |
Why?
|
| Busulfan | 3 | 2025 | 42 | 0.290 |
Why?
|
| Radiation Oncology | 4 | 2018 | 124 | 0.290 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 125 | 0.280 |
Why?
|
| Gallbladder Neoplasms | 1 | 2008 | 23 | 0.280 |
Why?
|
| Prostatic Neoplasms | 5 | 2020 | 1798 | 0.280 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2008 | 23 | 0.280 |
Why?
|
| Lymph Node Excision | 3 | 2020 | 234 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1087 | 0.270 |
Why?
|
| Clinical Clerkship | 3 | 2014 | 125 | 0.270 |
Why?
|
| Vidarabine | 2 | 2025 | 146 | 0.260 |
Why?
|
| Dacarbazine | 2 | 2017 | 101 | 0.240 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 81 | 0.240 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 67 | 0.240 |
Why?
|
| Vipoma | 1 | 2025 | 5 | 0.240 |
Why?
|
| Comorbidity | 3 | 2020 | 1011 | 0.230 |
Why?
|
| Shock | 1 | 2025 | 47 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 1023 | 0.220 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2005 | 96 | 0.220 |
Why?
|
| Regression Analysis | 3 | 2017 | 599 | 0.220 |
Why?
|
| Diarrhea | 1 | 2025 | 181 | 0.220 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 150 | 0.210 |
Why?
|
| Child, Preschool | 4 | 2015 | 3970 | 0.210 |
Why?
|
| Osteosarcoma | 1 | 2005 | 160 | 0.210 |
Why?
|
| Patient Selection | 2 | 2020 | 708 | 0.210 |
Why?
|
| Cisplatin | 2 | 2016 | 599 | 0.210 |
Why?
|
| Child | 5 | 2015 | 7618 | 0.200 |
Why?
|
| Prevalence | 3 | 2020 | 1349 | 0.200 |
Why?
|
| Meningioma | 1 | 2024 | 68 | 0.200 |
Why?
|
| Radiotherapy | 3 | 2016 | 325 | 0.200 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 73 | 0.200 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 17 | 0.200 |
Why?
|
| Postoperative Care | 2 | 2017 | 238 | 0.190 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 422 | 0.190 |
Why?
|
| Analysis of Variance | 3 | 2017 | 908 | 0.190 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 316 | 0.190 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 404 | 0.190 |
Why?
|
| Career Choice | 2 | 2014 | 163 | 0.180 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 121 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 579 | 0.170 |
Why?
|
| Mastectomy | 3 | 2015 | 270 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 40 | 0.170 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 43 | 0.170 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 11 | 0.170 |
Why?
|
| Neoplasms | 4 | 2017 | 3242 | 0.160 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2022 | 276 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 725 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 790 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 135 | 0.150 |
Why?
|
| Curriculum | 2 | 2014 | 615 | 0.150 |
Why?
|
| Risk Factors | 4 | 2020 | 5961 | 0.140 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2018 | 18 | 0.140 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 28 | 0.140 |
Why?
|
| Glossectomy | 1 | 2017 | 4 | 0.140 |
Why?
|
| Reward | 1 | 2020 | 209 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2024 | 2480 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 75 | 0.130 |
Why?
|
| Oral Surgical Procedures | 1 | 2017 | 19 | 0.130 |
Why?
|
| Minority Groups | 1 | 2018 | 154 | 0.130 |
Why?
|
| Thymoma | 1 | 2017 | 33 | 0.130 |
Why?
|
| Endosonography | 1 | 2017 | 101 | 0.130 |
Why?
|
| Functional Laterality | 1 | 2017 | 208 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2020 | 298 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2015 | 245 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 187 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 47 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1096 | 0.120 |
Why?
|
| Bronchi | 1 | 2017 | 234 | 0.120 |
Why?
|
| Margins of Excision | 1 | 2016 | 45 | 0.120 |
Why?
|
| Prostate | 1 | 2020 | 423 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 36 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3639 | 0.120 |
Why?
|
| Time Factors | 2 | 2017 | 5561 | 0.120 |
Why?
|
| Private Sector | 1 | 2015 | 21 | 0.120 |
Why?
|
| Taxoids | 1 | 2016 | 129 | 0.120 |
Why?
|
| Head | 1 | 2016 | 131 | 0.120 |
Why?
|
| Carboplatin | 1 | 2016 | 328 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 104 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 995 | 0.110 |
Why?
|
| Social Class | 1 | 2016 | 145 | 0.110 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 14 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2017 | 713 | 0.110 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 50 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 166 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.110 |
Why?
|
| Mesothelioma | 1 | 2018 | 333 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2015 | 220 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 192 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 218 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 360 | 0.110 |
Why?
|
| Community Health Services | 1 | 2015 | 81 | 0.110 |
Why?
|
| Needs Assessment | 2 | 2014 | 171 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2016 | 549 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 47 | 0.110 |
Why?
|
| Program Evaluation | 2 | 2014 | 323 | 0.110 |
Why?
|
| Graft Survival | 1 | 2018 | 942 | 0.110 |
Why?
|
| Students, Medical | 3 | 2014 | 455 | 0.100 |
Why?
|
| Necrosis | 1 | 2014 | 210 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 353 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2859 | 0.100 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 490 | 0.100 |
Why?
|
| Sex Factors | 2 | 2021 | 1127 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2025 | 415 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2014 | 275 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 228 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 318 | 0.090 |
Why?
|
| Length of Stay | 1 | 2015 | 833 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2014 | 854 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 178 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2015 | 413 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1805 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 372 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2010 | 7 | 0.080 |
Why?
|
| Thoracic Wall | 1 | 2010 | 27 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 750 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2592 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1211 | 0.070 |
Why?
|
| Gastrectomy | 2 | 2017 | 70 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 161 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 1816 | 0.060 |
Why?
|
| Retinoblastoma | 1 | 2005 | 31 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 43 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2005 | 42 | 0.060 |
Why?
|
| Biopsy | 1 | 2008 | 1208 | 0.050 |
Why?
|
| Allografts | 2 | 2015 | 207 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1615 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2025 | 368 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1957 | 0.050 |
Why?
|
| Medicaid | 2 | 2015 | 260 | 0.040 |
Why?
|
| Cetuximab | 1 | 2022 | 119 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2012 | 108 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2021 | 38 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 88 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 243 | 0.040 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.040 |
Why?
|
| Chicago | 2 | 2016 | 1505 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 48 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2611 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 1380 | 0.040 |
Why?
|
| Infant | 1 | 2005 | 3360 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 41 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 296 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 815 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 106 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 4664 | 0.030 |
Why?
|
| Melphalan | 1 | 2017 | 99 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 348 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 270 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 458 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 361 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 649 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 370 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 80 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 154 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2015 | 90 | 0.030 |
Why?
|
| Esophagus | 1 | 2016 | 111 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 144 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 67 | 0.030 |
Why?
|
| Professional Practice | 1 | 2015 | 45 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 66 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 252 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 61 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2039 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 39 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 933 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 32 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 644 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 196 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 119 | 0.020 |
Why?
|
| Self Concept | 1 | 2014 | 137 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 136 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1079 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1319 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 45 | 0.020 |
Why?
|
| Heart | 1 | 2016 | 590 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 381 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2013 | 101 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 196 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 340 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 644 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 2015 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 417 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 367 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 353 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2385 | 0.010 |
Why?
|